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Abstract
Microarray experiments designed to identify genes differentially expressed in the E11.5 lung and trachea showed that melanoma inhibitory
activity (Mia1) was expressed only in the lung. Mia1 was abundantly expressed during early lung development, but was virtually absent by the
end of gestation. Distal embryonic lung epithelium showed high levels of Mia1 expression, which was suppressed by treatment with either
retinoic acid or the FGF signaling antagonist SU5402. Late-gestation fetuses in which lung epithelial hyperplasia was induced by misexpression of
FGF7 or FGF10 showed continued expression of Mia1 in areas of aberrant morphogenesis. Mia1 expression was also significantly increased in
urethane-induced lung adenomas. Treatment of E18.5 lung explants with exogenous MIA caused significant reductions in the expression of the
lung differentiation markers Sftpa, Sftpb, Sftpc, and Abca3. Bitransgenic mice expressing MIA under the control of the SFTPC promoter after
E16.5, the age when Mia1 is normally silenced, died from respiratory failure at birth with morphologically immature lungs associated with
reduced levels of saturated phosphatidylcholine and mature SP-B. Microarray analysis showed significant reductions in the expression of Sftpa,
Sftpb, Abca3, Aqp5, Lzp-s, Scd2, and Aytl2 in lungs misexpressing MIA. These results suggest that the silencing of Mia1 that occurs in late
gestation may be required for maturation of the surfactant system.
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The embryonic mouse lung begins as paired evaginations
from the floor of the foregut endoderm on day E9.5 of gestation.
A series of dichotomous and lateral branchings gives rise to the
pulmonary tree, which is followed by a period of alveolization
that continues postnatally. Concomitant with the processes of
branching morphogenesis and alveolization is the differentia-
tion of specialized epithelial cell types. Experiments using
techniques in both classical embryology and molecular biology
have shown that lung branching morphogenesis and epithelial
differentiation are induced by diffusible cues produced by the
associated pulmonary mesenchyme (Rudnick, 1933; Shannon⁎ Corresponding author. Fax: +513 636 7868.
E-mail address: john.shannon@chmcc.org (J.M. Shannon).
0012-1606/$ - see front matter © 2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2008.02.003et al., 1998; Spooner and Wessells, 1970). Identification of the
molecules regulating lung morphogenesis and differentiation
has been a subject of intense interest. These include a large
number of diffusible signaling molecules as well as components
of the extracellular matrix (ECM) (for reviews see (Cardoso and
Lu, 2006; Shannon and Hyatt, 2004; Warburton et al., 2003).
All of these factors must be expressed in the correct place and at
the proper time for normal lung development to occur.
In experiments using tissue recombinants (Shannon, 1994;
Shannon et al., 1998) and mesenchyme-free culture (Deterding
and Shannon, 1995; Hyatt et al., 2004), we have demonstrated
that the entire embryonic respiratory tract epithelium, from the
trachea to the distal lung tips, exhibits substantial plasticity in its
eventual phenotype that is dependent on the inductive cues it
receives from its associated mesenchyme. This observation led
us to speculate that the differences between embryonic trachea
442 S. Lin et al. / Developmental Biology 316 (2008) 441–455and lung are defined by limited subset of genes, and that the
molecular comparison of these two tissues might provide new
information on genes that are important for both lung and
trachea development. In the present study we used microarray
analysis to identify genes differentially expressed in the
embryonic lung and trachea. We provide detailed analysis of
one of these differentially expressed genes, melanoma inhibi-
tory activity (Mia1), also known as cartilage-derived retinoic
acid-sensitive protein (CD-RAP). Our results demonstrate that
Mia1 is a developmentally regulated, FGF-sensitive ECM
protein whose expression is associated with areas of morpho-
genetic expansion in the normal lung, in lungs with FGF-
induced hyperplastic growth, and in carcinogen-induced lung
adenomas. We also present in vivo and in vitro data suggesting
that MIA can suppress distal lung epithelial maturation when
misexpressed during late gestation.
Materials and methods
Microarray analysis
Lung vs. trachea
Lung/trachea complexes were removed from day E11.5 FVB/N mouse
embryos, and then further dissected to produce distinct lung and trachea
populations. Lung tissue was defined as everything caudal to, but not including,
the primary bronchi. Trachea tissue was defined as that caudal to the prospective
larynx and cranial to the bifurcation; this strategy defined two spatially distinct
tissue populations. Tissues were lysed in 4 M guanidinium isothiocyanate and
centrifuged over a cushion of 5.7 M CsCl; the purified RNAwas then transferred
to the Affymetrix GeneChip Core Facility at Cincinnati Children’s Hospital
Medical Center for oligonucleotide microarray hybridization. Affymetrix
Murine Genome U74v2A chips were used according to the manufacturer’s
protocol to compare lung and trachea gene expression. Affymetrix Microarray
Suite version 5.0 was used to scan and quantify the gene chips. Three separate
hybridizations of paired tissue samples (lung and trachea) were used to generate
the results. Data from all chips were applied to two-step normalization to remove
or minimize systemic sources of variation at both the chip and gene level.
Specifically, we chose the 50th percentile (median of all genes distribution) as
the baseline for per chip normalization, followed by normalizing each gene to
the median of this gene across pair-wise designed experiments. Genes that were
differentially expressed between lung and trachea were identified by the
combination of distribution of distribution analysis (JMP4, SAS Institute, Cary,
NC) and/or Welch ANOVA with the cutoff p value b0.05 (Gene Spring 4.2.1,
Silicon Genetics, Redwood City, CA). Candidates were further filtered by their
reproducibility and their absolute intensity. The coefficient variation (CV) was
calculated for replicates of each gene and replicates with a CVN50% were
removed. Genes displaying extremely low signals in both control and sample
groups were eliminated as experimental noise.
SP-C/MIA vs. control
Lung cRNA from SP-C/MIA (described below) and control mice was
generated and hybridized to Affymetrix murine genome MOE430 chips
according to the manufacturer’s protocol. We analyzed cRNA from three
independent SP-C/MIA and three control lungs. Affymetrix Microarray Suite
5.0 was used to scan and quantify the gene chips under default scan settings.
Normalization was performed using the Robust Multichip Average model
(Irizarry et al., 2003a,b). Data were further analyzed using AfflmGUI (Linear
Models for Microarray Data) and Genespring GX 7.3 (Silicon genetics))
(Smyth, 2004). Differentially expressed genes were selected with the threshold
of t-test P≤0.05, False Discovery Rate (FDR) ≤10% and fold change ≥1.5.
Differentially expressed genes were subjected to functional classification
according to the Biological Process terms in Gene Ontology database. Gene
Ontology Analysis was preformed using public available web-based tool David
(database for annotation, visualization, and integrated discovery) (Dennis et al.,
2003). Overrepresented biological processes were selected at the threshold ofFisher Exact Test P-value ≤0.05 and minimum gene counts belonging to an
annotation term ≥5.
Explant cultures
In experiments testing the effects of retinoic acid onMia1 expression, lungs
from E11.5 FVB/N embryos were cultured on 8-μmWhatman nucleopore filters
(Whatman International, Clifton, NJ) placed in dissecting dishes. Lungs were
cultured for up to 4 days in serum-free BGJb medium (GIBCO/Invitrogen,
Carlsbad, CA) in the presence or absence of all-trans retinoic acid (Sigma
Chemical Co., St. Louis, MO) at concentrations of 10−6 and 10−5 M. In
experiments evaluating FGF signaling, E12.5 lungs were cultured for 1 day in
medium containing either 10 μM SU5402, or 20 μM LY294002, or 20 μM
UO126 (all from Calbiochem, La Jolla, CA), or DMSO as a vehicle control. In
experiments testing the effects of exogenous MIA on epithelial differentiation,
lungs from E18.5 embryos were isolated, cut into 1 mm3 explants and cultured
for 48 h in serum-freeWaymouth’s medium (GIBCO/Invitrogen) in the presence
or absence of 500 ng/ml recombinant human MIA. Recombinant human MIA
(Gly25–Gln131) was generated in Escherichia coli, renatured, and purified by
chromatography and gel filtration as previously described (Bauer et al., 2006).
Protein purity was checked by SDS-PAGE and HPLC and was shown to be 95%
pure.
Tissue recombinations
Tissue recombinants composed of lung mesenchyme plus either lung
epithelium or tracheal epithelium were prepared as previously described
(Shannon et al., 1998). Briefly, day E11.5 distal lung tips were removed and
incubated with dispase (BD Biomedical) for 30 min at 37 °C, then separated into
purified epithelial and mesenchymal components using tungsten needles. Day
E11.5 tracheae were bisected, incubated for 45 min at 37 °C in DMEM/F12
containing 0.05% collagenase IV (Worthington Biochemicals, Freehold, NJ)
and 1% FBS (Sigma), then separated into epithelial and mesenchymal
components using tungsten needles. Both lung and tracheal epithelial rudiments
were treated a second time with dispase for 10 min to remove any residual
adherent mesenchymal cells. Tissues were recombined on the surface of a
semisolid medium consisting of DMEM/F12 containing 0.5% agarose and 5%
FBS. Dishes containing tissue recombinants were placed in humidified 150 mm
diameter dishes and cultured for up to 5 days.
Mesenchyme-free culture of embryonic lung epithelium
Distal lung epithelium was isolated from the tips of E12.5 lungs by digestion
with dispase followed by dissection with tungsten needles as previously
described (Deterding and Shannon, 1995). The epithelial rudiments were
enrobed in Matrigel (Invitrogen) and cultured for 7 days in DMEM/F12 medium
containing 5% charcoal-stripped FBS, insulin 10 μg/ml, cholera toxin 1 μg/ml,
human recombinant epidermal growth factor (EGF) 25 ng/ml, human
recombinant hepatocyte growth factor (HGF) 10 ng/ml, FGF7 (Peprotech)
25 ng/ml and FGF1 100 ng/ml. This culture system stimulates embryonic lung
epithelial proliferation and differentiation (Shannon et al., 1999). Experimental
cultures were treated with SU5402 for the last 24 h.
Transgenic mice
All mice used in these studies were generated on an FVB/N background.
Mice bearing transgenes that allowed the inducible expression of FGF7
(Tichelaar et al., 2000) and FGF10 (Clark et al., 2001) were kindly provided
by Dr. Jeff Whitsett (Cincinnati Children’s Hospital). Briefly, permanent lines of
activatormice have been established in which the 3.7 kb human SFTPC promoter
or 2.3 kb ratCCSP promoter drive expression of a reverse tetracycline responsive
transactivator (hereafter SP-C/rtTA or CCSP/rtTA, respectively). Two separate
responder lines were also established, bearing either a (tetO)7/cmv/FGF7 or a
(tetO)7/cmv/FGF10 transgene. These transgenes consist of seven copies of the
tet operator, a minimal cmv promoter, either the human FGF7 or the mouse
FGF10 coding sequence, and a SV40 polyadenylation signal. Activator and
responder mice were bred to generate bitransgenic fetuses (hereafter SP-C/FGF7
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pregnant dams via drinking water beginning on day E10.5. Fetuses were
harvested on day E18.5. Doxycycline crossed the placenta and allowed the rtTA
fusion protein to bind the tet operator, activating the cmv promoter, which in turn
drove expression of FGF7 or FGF10 in bitransgenic fetal lungs.
In order to study the effect of continued MIA expression during late lung
development, we generated mice bearing an inducible Mia1 transgene. The
transgene comprised 430 bp of murine Mia1 cDNA followed by a Flag tag
(DYKDDDDK), which was cloned into the tet-responsive vector pTRE-HA
vector (Clontech). Prior to injection, a 2.2 kb fragment containing the (tetO)7/
cmv promoter, Mia1 cDNA, Flag tag and the β-globin poly A tail was released
from the vector by AatII/SapI digestion and gel-purified. Purified DNA was
microinjected into fertilized FVB/N mouse eggs by the Cincinnati Children’s
Hospital Transgenic Core Facility. Founder mice were identified by two sets of
PCR amplification of mouse tail DNA using 5′-primers specific to either the
cmv promoter (5′-TTTTGACCTCCATAGAAGACACCG-3′) or the Mia1
coding sequence (5′-TTTCCCCAGTAGCATTGTCCG-3′) and a 3′-primer
specific to the β-globin poly A tail (5′-CTACATCCTGGTAATCATCCTGCC-
3′) to generate 1050 bp or 600 bp products, respectively. Five founder lines of
tetO/MIA responder mice were generated; we selected the line that displayed the
most robust expression of MIA for further study. The tetO/MIA responder mice
were mated with SP-C/rtTA activator mice to generate bitransgenic progeny
(hereafter SP-C/MIA mice) expressing MIA in a doxycycline-inducible manner.
Dox was added on day E15.5 to ensure MIA expression in distal epithelia on day
E16.5 and later. Single transgenic littermates (those expressing only the SP-C/
rtTA or tetO/MIA transgene) served as controls.
Generation of lung tumors
Lung tumors were produced by treating 8-week-old strain A/J mice with a
single intraperitoneal injection of urethane (Sigma) dissolved in 0.9% NaCl at a
dose of 1 mg/g body weight (Malkinson and Beer, 1983). Mice were sacrificed
44 weeks following urethane injection and tumors harvested. Uninvolved tissue
adjacent to the tumors and lung tissue from age-matched vehicle treated animals
served as controls.
In situ hybridization
The murine cDNAs for Mia1 (580 bp) and Sftpc (758 bp) were used as
templates for generating riboprobes. Digoxigenin-labeled probes were used for
whole mount in situ hybridization (ISH), which was performed as described by
Wilkinson (1992). Tissue section ISH was performed as previously described
(Deterding and Shannon, 1995), with the exception that 33P-UTP was used for
labeling the probe.
Quantitative RT-PCR
Mia1 expression was assessed by quantitative real-time PCR (qRT-PCR).
Template cDNAs were obtained by reverse transcriptase reaction (cDNA Cycle
kit, Invitrogen) of total RNAs from E11.5 lung and trachea. Amplification was
carried out using the DNA master SYBR green I mix (Roche Molecular
Biochemicals). The template was mixed with 1× SYBRmix, 2.5 mMMgCl2 and
0.25 μM each probe. All reactions were performed in a Smart Cycler (Cepheid,
Sunnyvale, CA). Reaction conditions were 95 °C for 150 s, followed by 40 cycles
of amplification (95 °C for 10 s, 58–60 °C (depending on primer set) for 15 s and
72 °C for 20 s). Data were normalized to β-actin or the amount of input cDNA.
The sequences of the primers used were as follows:
Mia1, sense: 5′-TCCTTGGCATCGTCGTCTTGTC-3′,
antisense: 5′-CCATAGTAACCTCCCTGAACACTGC-3′;
Sftpa, sense: 5′-AGTCCTCAGCTTGCAAGGATC-3′,
antisense: 5′-CGTTCTCCTCAGGATTCCTCG-3′;
Sftpc, sense: 5′-CATCGTTGTGTATGACTACCAGCG-3′,
antisense: 5′-GAATCGGACTCGGAACCAGTATC;
Sftpb, sense: 5′-CTGTGCCAAGAGTGTGAGGA-3′,
antisense: 5′-TTGGGGTTAATCTGGCTCTG-3′;
Abca3, sense: 5′-TTCAACAACCAGGCATACCA-3′,antisense: 5′-AGCAAATTGAGGGCAATGTC-3′;
Dusp9, sense: 5′-TTCCTCCTCCCCCAGATGTC-3′,
antisense: 5′-CCCCAAACCAACAGTGGCTG-3′;
β-actin, sense: 5′-TGGAATCCTGTGGCATCCATGAAAC-3′,
antisense: 5′-TAAAACGCAGCTCAGTAACAGTCCG-3′
Quantification of Mia1 expression in urethane-induced lung tumors and in
the SU5402-treated lung epithelium experiments was done using an Applied
Biosystems 7300 instrument and TaqMan Gene Expression Assays (Applied
Biosystems, Foster City, CA), as was quantification of Ptch1 in the E11.5 lung
and trachea. Reaction conditions were 50 °C for 120 s, 95 °C for 10 min, then 40
cycles of amplification (95 °C for 15 s and 60 °C for 60 s).Mia1 expression was
normalized to β-actin.
Western blotting
Lungs were snap frozen in liquid nitrogen, ground with mortar and pestle in
ice-cold 1× PBS containing 1× protease inhibitor (Roche) and 1% NP-40
(Sigma), followed by sonication. Samples were centrifuged and protein
concentration determined by BCA analysis. Immunoblots of total lung
homogenate from SP-C/MIA and control littermates were prepared by
electrophoresing 20 μg of total protein from lung homogenates by SDS-
PAGE and transferring it to nitrocellulose. Western blots were performed using
antiserum 28031, which is directed against mature SP-B (Lin et al., 1996), at a
dilution of 1:15,000.
Immunohistochemistry
Paraffin sections were immunostained with the following antibodies: anti-
FLAG (1:2000; Sigma), anti-T1α (1:500; Developmental Studies Hybridoma
Bank, Iowa City, IA), and anti-SP-B (antibody 28031, 1:1000). Biotinylated
anti-rabbit secondary antibody was used along with Vectastain ABC kit (Vector
Laboratories) to visualize staining.
Morphometry
Morphometric measurements were performed on E18.5 lungs from four SP-
C/MIA and four single transgenic fetuses. The overall proportion (% fractional
area) of respiratory parenchyma and airspace was determined by using point
counting method (Bolender et al., 1993; Wert et al., 2000) on two sections taken
at intervals throughout the left or right lobes. Images (fields) were transferred by
video camera to a computer screen using Metamorph imaging software
(Universal Imaging, West Chester, PA). A computer-generated, 121-point lattice
grid was superimposed on each field, and the number of intersections (points)
falling over respiratory parenchyma (alveoli and alveolar ducts) or airspace was
counted. Points falling over bronchioles, large vessels and smaller arterioles and
venules were excluded from the study. Fractional areas (% fractional area) were
calculated by dividing the number of points for each compartment (n) by the
total number of points contained within the field (N), and then multiplying by
100: % fractional area=n/N×100. Epithelial and mesenchymal cells were
counted manually. Ten to twenty fields per section were analyzed to gather the
data; more than 500 cells were analyzed for each tissue compartment.
Phospholipid analysis
Lungs were homogenized in 0.9% NaCl and then the protease inhibitor
P8340 (1:100, Sigma) was added to the homogenate. Lipids were extracted from
the homogenate (Bligh and Dyer, 1959), and phospholipid composition was
determined by 2-D thin-layer chromatography (Ikegami et al., 2003). Saturated
phosphatidylcholine was isolated from lipid extracts using the osmium tetroxide
method (Mason et al., 1976) followed by a phosphorus content assay (Bartlett,
1959).
Statistics
All data were statistically analyzed using GraphPad Prizm version 4.0
(GraphPad Software, San Diego, CA). Data from SU5402-treated epithelium
Table 1
Genes upregulated in embryonic mouse lung vs. trachea
GenBank
accession #
Fold
change
Symbol Gene
Transcription factors
NM_008269 6.0 Hoxb6 Homeobox B6
NM_010426 2.5 FoxF1a Forkhead box F1a
NM_009538 2.1 Plagl1 Pleiomorphic adenoma gene like 1
NM_010703 2.1 Lef1 Lymphoid enhancer binding factor 1
NM_011415 2.1 Snai2 Snail homolog 2
NM_009331 1.8 Tcf7 Transcription factor 7
NM_008584 1.5 Meox2 Mesenchyme homeobox 2
Development
NM_009152 4.2 Sema3a Semaphorin 3a
NM_010025 3.2 Dcx Doublecortin
NM_008957 2.2 Ptch1 Patched homolog 1
NM_053089 2.1 Narg1 NMDA receptor regulated gene 1
NM_009510 2.1 Vil2 Villin 2
NM_010060 1.7 Dnahc11 Dynein, axonemal, heavy chain 11
NM_011199 1.6 Pthr1 Parathyroid hormone receptor 1
NM_007555 1.6 Bmp5 Bone morphogenetic protein 5
Cell adhesion
NM_019934 12.9 Mia1 Melanoma inhibitory activity 1
NM_008485 3.0 Lamc2 Laminin, gamma 2
NM_009902 2.2 Cldn3 Claudin 3
AF041409 2.0 Itga8 Integrin alpha 8
NM_018777 1.9 Cldn6 Claudin 6
Signal transduction
NM_010305 2.0 Gnai1 Guanine nucleotide binding protein
NM_053272 2.0 Dhcr24 24-dehydrocholesterol reductase
NM_011945 1.7 Map3k1 Mitogen activated protein kinase
kinase kinase 1
NM_133235 1.7 Khdrbs2 KH domain containing, RNA binding,
signal transduction
Associated 2
NM_010579 1.5 Itgb4bp Integrin beta 4 binding protein
Protein metabolism
NM_009183 2.4 St8sia4 ST8 alpha-N-acetyl-neuraminide
alpha-2,8-sialyltransferase 4
NM_025553 2.4 Mrpl11 Mitochondrial ribosomal protein L11
NM_029352 2.2 Dusp9 Dual specificity phosphatase 9
NM_152804 1.9 Plk2 Polo-like kinase 2 (Drosophila)
NM_026130 1.9 Srpr Signal recognition particle receptor
NM_025338 1.7 Aurkaip1 Aurora kinase A interacting protein 1
NM_026332 1.6 Dnajc19 DnaJ homolog, subfamily C, Member 19
DNA/RNA metabolism
NM_009104 2.0 Rrm2 Ribonucleotide reductase M2
NM_010931 1.9 Uhrf1 Ubiquitin-like, containing PHD and RING
finger domains, 1
NM_019870 1.5 Ard1 N-acetyltransferase ARD1 homolog
NM_138586 1.5 Exosc5 Exosome component 5
Other proteins
NM_013492 8.7 Clu Clusterin
NM_011359 5.9 Sftpc Surfactant associated protein C
NM_021301 2.9 Slc15a2 Solute carrier family 15, member 2
NM_008471 2.4 Krt19 Keratin 19
NM_013820 2.2 Hk2 Hexokinase 2
NM_010284 2.0 Ghr Growth hormone receptor
NM_026323 1.9 Wfdc2 WAP four-disulfide core domain 2
NM_133706 1.9 Temem97 Transmembrane protein 97
Table 1 (continued)
GenBank
accession #
Fold
change
Symbol Gene
Other proteins
NM_010390 1.6 H2-Q1 Histocompatibility 2, Q region 1
NM_009171 1.6 Shmt1 Serine hydroxymethyltransferase 1
NM_016737 1.6 Stip1 Stress-induced phosphoprotein 1
NM_177420 1.5 Psat1 Phosphoserine aminotransferase 1
ESTs
BB645708 2.3 B430320C24
AK008780 1.9 2210039B01Rik
NM_026063 1.5 2900010M23Rik
444 S. Lin et al. / Developmental Biology 316 (2008) 441–455cultures, saturated phosphatidylcholine content, and morphometry were
analyzed using unpaired t-tests. Data from lung explant cultures treated with
RA, or with DMSO, SU5402, LY294002 and UO126, or with recombinant MIA
were analyzed by one-way ANOVA, as were the lung tumor Mia1 content
experiments.Results
Differential gene expression in the E11.5 lung
Statistical comparison of the genes expressed in the E11.5
mouse lung vs. trachea resulted in the identification of 51 genes
that were upregulated in the lung. These comprised 48 known
genes and 3 ESTs. As shown in Table 1, the known genes
included transcription factors (7), signal transduction proteins
(5), proteins associated with development (8), cell adhesion
proteins (5), proteins involved in processing of nucleic acids
and proteins (11), and other proteins (12) with various
functions. One of the proteins identified as lung-specific was
surfactant protein C (Sftpc), which has been shown by a variety
of techniques to be expressed only in the lung epithelium
(Kalina et al., 1992; Wert et al., 1993). qRT-PCR confirmed the
differential expression of SP-C, along with two other genes
identified in the microarray, Dusp9 (2.9-fold) and Ptch1 (3.2-
fold). Taken together, these results indicated that the microarray
hybridization was performing as intended.
One of the largest differences in gene expression we
observed in the E11.5 lung vs. trachea was melanoma inhibitory
activity (Mia1) (Blesch et al., 1994), also known as cartilage-
derived retinoic acid sensitive protein (CD-RAP) (Dietz and
Sandell, 1996). MIA is a secreted protein, which suggested that
it could play a role in mediating cell–cell interactions.
Furthermore, Mia1 expression is regulated by RA, which is
known to play a major role in lung morphogenesis (Mendelsohn
et al., 1994; Mollard et al., 2000). We therefore examined Mia1
expression during lung development.
Ontogeny of Mia1 in the lung
Previous studies had noted Mia1 expression in the
embryonic lung (Bosserhoff et al., 1997b; Xie et al., 2000),
and characterized the site of expression as being in cartilaginous
lung bronchi (Bosserhoff et al., 1997b). As shown by whole
445S. Lin et al. / Developmental Biology 316 (2008) 441–455mount ISH in Fig. 1, we found that Mia1 is expressed in the
endodermal epithelium of embryonic lung buds on day E10.5
(Fig. 1A). By day E11.5 (Fig. 1B) expression was restricted to
the lung parenchyma, and was particularly intense in the most
distal lung tips. Expression in the bronchi and trachea was not
observed, a result that was confirmed by qRT-PCR (data not
shown). This pattern of expression continued through day
E12.5 (Fig. 1C). On day E13.5 (Fig. 1D) Mia1 expression
persisted in the lung epithelium, but was also noted in the
incipient cartilaginous rings that were now developing in the
trachea and bronchi (Fig. 1D, arrowheads). Tissue section ISH
confirmed epithelial expression of Mia1 on days E14.5 and
E15.5 (Figs. 1E–H), and further revealed that distribution wasFig. 1. Ontogeny ofMia1 expression in the developing lung. Whole mount in situ hy
E10.5 (A), E11.5 (B), and E12.5 (C), but is not detected in the tracheal epithelium.
incipient tracheal cartilage (arrowheads). Panels A–D are at the same magnification;
not proximal (arrows) epithelium on days E14.5 (E, F) and E15.5 (G, H). On day E16
for Mia1 (I, J). On day E18.5 signal for Mia1 is seen in the proximal epithelium (
undetectable in the adult lung (O, P). Panels E–P are at the same magnification; banot uniform. The distal epithelium expressed Mia1, while the
proximal epithelium did not (arrows, Fig. 1H). An abrupt
change in the pattern of Mia1 expression was seen on day
E16.5, when it was seen only in the most distal epithelial
tubules lying immediately under the pleural surface (Figs. 1I, J).
This pattern of expression continued until day E18.5, when
another change was seen: distal epithelial expression of Mia1
was extinguished, and expression in the large proximal airways
was detected, albeit at low levels (Figs. 1K, L). This pattern
persisted through birth (Figs. 1M, N). In agreement with
previous observations (Dietz and Sandell, 1996) we found that
Mia1 was essentially undetectable in the adult lung by ISH
(Figs. 1O, P).bridization (ISH) shows thatMia1 is expressed in lung distal epithelium on days
Epithelial expression continues on day E13.5 (D), but signal is also present in
bar=590 μm. Tissue section ISH shows that Mia1 is expressed in the distal but
.5 the expression pattern changes, and only the most distal epithelium is positive
K, L), a pattern that continues on postnatal day 1 (M, N). Mia1 is essentially
r=100 μm.
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We next determined the effect of RA on Mia1 expression in
cultured E11.5 lung explants. We treated explants with RA at
final concentrations of 10−6 M and 10−5 M, which have been
previously shown to disrupt branching morphogenesis and
arrest epithelial maturation in cultured embryonic lungs
(Cardoso et al., 1995; Malpel et al., 2000). E11.5 lungs
showed continued dichotomous and lateral branching when
cultured in serum-free medium for 4 days (Fig. 2B). These
explants showed maintenance of Mia1 expression, which was
most intense at the distal tips (Fig. 2C). Lung explants treated
with 10−6 M RA showed reduced branching (Fig. 2E), but the
overall pattern was still lung-like. Mia1 expression was still
evident in the distal epithelium of explants treated with 10−6
M RA (Fig. 2F), although the intensity of signal appeared
reduced in comparison to controls. Lungs treated with 10−5 M
RA were smaller than controls and lung branching was clearly
reduced (Fig. 2H). The decreases in branching seen in 10−5 MFig. 2. Retinoic acid (RA) suppressesMia1 expression. Day E11.5 lungs (A, D, G) w
trans RA (E, F), or 10 μM RA (H, I). RA attenuates normal branching morphogenes
ISH shows that the distal epithelium of lungs cultured with no additions express hig
abolishes expression at 10 μM (I). All panels are at the same magnification; bar=300
and 1 μM RA) reduced in lungs cultured in medium containing 10 μM RA (J). DatRA-treated explants were accompanied by a clear diminution
in Mia1 expression (Fig. 2I). These graded effects of RA on
lung morphogenesis were consistent with what has been
previously reported (Cardoso et al., 1995). The decrease in
Mia1 expression we observed in response to RA was
detectable by day 2 of culture when measured by qRT-PCR
(Fig. 2J).
Mia1 expression is induced by lung mesenchyme
Our ISH and qRT-PCR data both demonstrated that Mia1,
like Sftpc, is not expressed in the developing tracheal
epithelium. We have previously shown that embryonic tracheal
epithelium recombined with distal lung mesenchyme was
reprogrammed to express both morphological and molecular
markers of differentiated distal lung epithelium, including Sftpc
(Shannon et al., 1998). We therefore examined tissue recombi-
nations to determine whetherMia1 expression was also induced
when tracheal epithelium had been reprogrammed to a distalere grown for 4 days in BGJb medium containing no additions (B, C), 1 μM all-
is at 1 μM (E), and significantly disrupts branching at 10 μM (H). Whole mount
h levels of Mia1 (C). RA diminishes Mia1 expression at 1 μM (F), and nearly
μm. qRT-PCR shows thatMia1 expression is significantly (*, pb0.05 vs. control
a are plotted as means±S.E. (n=3).
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distal lung tips cultured for 3 days branched within the
mesenchyme and expressed Mia1 (Figs. 3A, B). Recombinants
of distal tip lung epithelium and mesenchyme, which served as
surgery controls, showed normal epithelial branching and Mia1
expression in the distal tips (Figs. 3C, D). Tracheal epithelium
also branched in a lung-like pattern when recombined with lung
mesenchyme. The reprogrammed tracheal epithelium was
induced to express Mia1, and the level of expression appeared
identical to that seen in recombinants of distal tip lung
epithelium and mesenchyme (Figs. 3E, F). Like the early lung
in vivo, Mia1 expression was localized to the distal epithelial
tips in these recombinants. Identical to our previous experi-
ments (Shannon et al., 1998), recombination of tracheal
epithelium with lung mesenchyme also induced Sftpc expres-
sion in the distal tips at a level equivalent to that seen in
recombinants of lung epithelium and mesenchyme (data not
shown). These data demonstrate that Mia1 expression is
dependent on factors produced by the mesenchyme.Fig. 3. Induction of Mia1 in embryonic tracheal epithelium. Intact distal lung
tips, recombinations of E11.5 lung mesenchyme and lung epithelium, or
recombinations of E11.5 lung mesenchyme and tracheal epithelium were
prepared and cultured for 3 days. ISH of intact E11.5 distal lung tips (A, B) and
lung mesenchyme+lung epithelium recombinants (C, D) demonstrates that
Mia1 expression was sustained by lung epithelium in vitro. Recombination of
lung mesenchyme with E11.5 tracheal epithelium, which was negative forMia1
at the time of isolation (see Fig. 1), results in the induction of Mia1 in the
reprogrammed tracheal epithelium (E, F). All panels are at the same
magnification; bar=45 μm.Mia1 expression is FGF dependent
To determine ifMia1 is regulated by FGFs, we treated E12.5
lung explants for 24 h with the FGF receptor antagonist
SU5402. Using qRT-PCR, we found that blockade of FGF
signaling caused a significant decrease inMia1 expression (Fig.
4A). The two downstream signaling pathways of FGF signaling
that have been most thoroughly studied are the PI3-Kinase/Akt
and MAP Kinase/Erk pathways. To gain some insight into the
downstream effectors involved in regulating Mia1 expression,
we cultured E12.5 lungs for 1 day in the presence of either
SU5402, or LY294002 (a PI3K/AKT signaling inhibitor), or
UO126 (a MAPK/ERK signaling inhibitor). We found that all
three inhibitors significantly reduced the level of Mia1
expression (Fig. 4A). We also cultured purified E12.5 distal
lung epithelial rudiments for 7 days in a complex medium
containing FGF7 and FGF1, which we have previously shown
(Shannon et al., 1999) to support the differentiation of
embryonic lung endoderm. Treating these rudiments with
SU5402 for the last 24 h of culture reduced Mia1 expression
by 50% (Fig. 4B), indicating that FGFs directly regulate Mia1
expression.
Mia1 is expressed in the epithelium of embryonic lungs with
abnormal morphogenesis
Our ontogeny data showed thatMia1 expression was highest
during the embryonic and pseudoglandular stages of lung
development, when the epithelium is most actively invading and
ramifying within the mesenchyme. Mia1 expression was
extinguished in the lung parenchyma by the saccular stage on
day E18.5, when lung patterning has been largely completed.
These observations suggested that Mia1 expression might be
associated with epithelial invasion of surrounding mesenchyme.
Because our in vitro data showed thatMia1 expression was FGF
dependent, we examined this possibility in lungs from
bitransgenic fetuses in which normal epithelial patterning had
been compromised by misexpression of FGF7 or FGF10. Lungs
from E18.5 SP-C/FGF7 fetuses showed an increase in overall
size and generalized epithelial hyperplasia (Fig. 5C) that
resembled cystadenomatoid malformation (Tichelaar et al.,
2000). In contrast to control littermates, in which Mia1
expression was limited to the proximal epithelium at this stage
(Figs. 5A, B), virtually all of the epithelial cells in the lungs of
SP-C/FGF7 mice were positive forMia1 (Fig. 5D). Conditional
expression of high levels of secreted FGF10 by the lung
epithelium of CCSP/FGF10 mice gave a different morphology.
Although there was some widespread epithelial hyperplasia,
there were also focal adenoma-like lesions (Fig. 5E) inter-
spersed with normal lung parenchyma (Clark et al., 2001). The
adenomatous structures in these lungs were strongly positive for
Mia1 (Fig. 5F), whereas surrounding normal tissue remained
negative (Fig. 5F, asterisk). These observations confirmed that
Mia1 was FGF dependent in vivo, and that its expression
correlated with areas of active morphological changes.
In order to determine if Mia1 expression was affected in
independent lung tumors, we measured Mia1 content in
Fig. 4.Mia1 expression is directly regulated by FGFs. (A) Day E12.5 lungs were
grown for 1 day in BGJb medium containing DMSO, SU5402, LY294002, or
UO126. qRT-PCR shows that Mia1 expression is significantly (*, pb0.001 vs.
DMSO) reduced by SU5402, LY294002 and UO126. (B) Purified day E12.5
lung epithelial rudiments were grown for 6 days then treated with SU5402 for
1 day. qRT-PCR demonstrates that SU5402 significantly (*, p=0.004) reduced
Mia1 expression. Data are plotted as means±S.E. (n=4 for both panels A and B).
Fig. 5. Mia1 is expressed in regions of aberrant morphogenesis. Mia1
expression is restricted to the proximal epithelium in wild type E18.5 mice
(A, B). Inducible misexpression of FGF7 in the lung epithelium causes
widespread epithelial cell hyperplasia in E18.5 lungs (C), which is accompanied
by sustained expression of Mia1 in virtually all epithelial cells (D). Inducible
misexpression of FGF10 also causes epithelial cell hyperplasia (E), but in some
areas focal adenomatous lesions are surrounded by normal tissue (asterisk).
Mia1 is present in the areas of abnormal growth (F), but is absent in normal
tissue. All panels are at the same magnification. qRT-PCR shows that Mia1
expression is significantly (*, pb0.01 vs. control lung, #, pb0.01 vs. adjacent
lung) higher in independent lung tumors induced by urethane injection com-
pared to lung tissue from control animals injected with saline, and to unin-
volved lung tissue adjacent to the tumors (G). Data are plotted as means±S.E.
(n=5).
448 S. Lin et al. / Developmental Biology 316 (2008) 441–455urethane-induced lung adenomas (Fig. 5G). We found that
Mia1 expression was increased over 10-fold compared to lung
tissue from vehicle treated adults. We also measured Mia1
content in tissue adjacent to the adenomas where no obvious
tumors were apparent. Although Mia1 expression appeared to
be increased over controls in this tissue, these differences did
not reach statistical significance (n=5).
MIA inhibits type II cell differentiation and lung maturation in
vitro
The fact that Mia1 is absent in the distal epithelium in late
gestation suggested the possibility that silencing of Mia1 may
be required for lung maturation. Previous studies have shown
that MIA inhibits the interaction of integrins with fibronectin
and laminin (Bauer et al., 2006; Bosserhoff et al., 2003b).
Furthermore, a number of studies have shown that type II cell
differentiation requires interaction with ECM components,
particularly laminin (Nguyen et al., 2005; Olsen et al., 2005;
Shannon et al., 1990). We speculated that excessive production
of MIA in late gestation could prevent type II cells from
interacting with laminin and therefore inhibit type II cell
differentiation. To test this possibility, we cultured E18.5 lung
explants in the presence or absence of recombinant human MIA
to determine if the expression of several distal epithelial
differentiation markers was affected. Explants treated with
500 ng/ml MIA appeared identical to controls, and we observed
no morphological changes indicating toxicity. We found (Fig. 6)
that MIA significantly reduced expression of Sftpa (p=0.02,
n=4), Sftpb (p=0.02, n=3), Sftpc (p=0.04, n=4), and Abca3
(p=0.05, n=4), suggesting that MIA inhibited type II cell
differentiation.Mice misexpressing MIA die from respiratory failure
To test whether excess MIA could similarly affect type II cell
differentiation in vivo, we generated bitransgenic mice that
inducibly expressed MIA under the control of the Sftpc
promoter. Misexpressing MIA in the lung epithelium of SP-C/
Fig. 6. MIA downregulates surfactant gene expression. Explants of E18.5 lungs
were cultured for 2 days in the presence or absence of 500 ng/ml recombinant
MIA. qRT-PCR demonstrates that expression of Sftpa, Sftpb, Sftpc and Abca3 is
significantly (*, pb0.05) reduced in lungs cultured in medium containing MIA.
Data are plotted as means±S.E. (n=4).
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normally extinguished, resulted in death from respiratory failure
in 100% of the neonates. Animals were cyanotic at birth and
died within minutes. No deaths were observed in neonates
bearing single SP-C/rtTA or Otet/MIA transgenes, or in SP-C/
MIA neonates whose mothers were not given Dox. Histology of
the lungs from E18.5 fetuses (Figs. 7A, B) revealed pronounced
mesenchymal thickening and decreased alveolar space, obser-
vations that were confirmed morphometrically (Figs. 7C, D).
We observed no morphological abnormalities in SP-C/rtTA or
Otet/MIA single transgenic mice. Histochemical staining ofFig. 7. Misexpression of Mia1 results in mesenchymal thickening and reduced alve
beginning on E16.5 and continued until sacrifice at E18.5. Histology shows that the
compared to single transgenic (expressing only the tetO/MIA transgene) littermate
parenchyma in the E18.5 lungs show that SP-C/MIA double transgenic (DT) mice h
single transgenic (ST) mice (C). Comparison of total cell number show that total mes
to controls while no significant differences are observed in total epithelial cells betwlung sections from SP-C/MIA and control mice showed that the
epithelial cells of the double transgenic mice contained copious
amounts of glycogen (data not shown). Since the content of
glycogen, which serves as a substrate for surfactant phospho-
lipid biosynthesis, decreases in late gestation (Bourbon et al.,
1982), these data were consistent with impaired maturation of
the surfactant system.
Immunostaining demonstrated that mature SP-B protein
was significantly reduced (Figs. 8C, D) in the distal epithe-
lium of bitransgenic mice in areas where transgene expression
was detected by FLAG immunostaining (Figs. 8A, B). West-
ern blot analysis confirmed that mature SP-B was decreased
in bitransgenic mice compared to controls (wild type mice
and mice singly expressing either a SP-C/rtTA or tetO/MIA
transgene) (Fig. 8G). Immunostaining for T1α, a type I cell
marker, also appeared unaffected in the lung epithelium (Figs.
8E, F). We assessed the overall phospholipid composition in
the lungs of SP-C/MIA mice and control littermates and
found that there were no significant differences between
the two groups (data not shown). However, comparison of the
content of saturated phosphatidylycholine (SatPC), the
predominant phospholipid of pulmonary surfactant, in the
lungs of SP-C/MIA mice and control littermates showed (Fig.
8H) that the lungs of bitransgenic mice contained only 40%
of the SatPC found in controls. These data indicated that
misexpression of MIA in the distal epithelium after day E16.5
inhibited several aspects of maturation of the surfactant
system.
To assess the effect of misexpressing MIA on overall lung
gene expression, we analyzed RNA from day E18.5 lungs of
bitransgenic and control littermates by microarray (Affymetrixolar space. Mia1 expression was induced in the epithelium of SP-C/MIA mice
lung mesenchyme in SP-C/MIA double transgenic fetuses (B) appears thickened
s (A). Comparison of changes in fractional areas of airspace and respiratory
ave significantly (*, pb0.001) more parenchyma and less airspace compared to
enchymal cells are significantly (*, pb0.01) higher in SP-C/MIA mice compared
een the two groups (D). Data are plotted as means±S.E. (n=4).
Fig. 8. Gene expression in SP-C/MIA mice. Immunostaining of E18.5 lung sections for FLAG identifies epithelial cells misexpressing Mia1 (B), whereas single
transgenic controls show no signal (A). Immunostaining for mature SP-B shows widespread expression in single transgenic (expressing only the tetO/MIA transgene)
controls (C). SP-C/MIA mice, however, show greatly reduced SP-B staining (D), a finding that is confirmed by Western blot (G). Immunostaining for the type I cell
marker T1α appears similar in both single transgenic and SP-C/MIA mice (E, F). All panels are at the same magnification. Comparison of the content of saturated
phosphatidylcholine (SatPC) in the lungs of SP-C/MIAmice and controls demonstrates that the lungs of SP-C/MIAmice contain only 40% (*, pb0.0001) of the SatPC
found in single transgenic controls. Data are plotted as means±S.E. (n=6 for SP-C/MIA mice and 7 for controls).
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least 1.5-fold and 87 genes that were increased for more than
1.5-fold in bitransgenic lungs (Table 2). Downregulated genes
potentially relevant to the phenotype of respiratory failure
included surfactant proteins (Sftpa, Sftpb), proteins involved in
phospholipid production (Abca3, Aytl2, and Scd2), proteins
related to other aspects of lipid metabolism (Acoxl, Pon1,
Gdpd2, Dlk1), and Cebpa. Upregulated genes potentially
relevant to the phenotype included Mia1 (30-fold), along with
genes involved in cell adhesion (Dsg2, Dcbld2, Cdh1, Cdh8,
Cdh16). The overall gene expression profile was consistent
with retarded lung maturation.Discussion
In this study we compared transcriptomes in the E11.5 lung vs.
trachea in order to identify differentially expressed genes. This
choice of these two tissues was based on our previous studies
(Shannon et al., 1998), which showed that the entire respiratory
endoderm at this stage will adopt the fate specified by the
mesenchyme with which it is associated. We reasoned that
number of genes differentially expressed between these tissues
would be limited, and that those genes found to be upregulated in
the E11.5 lung might be important in defining the lung phenotype
at this stage in development. Among the diverse panel of genes
Table 2
Genes changed by misexpression of MIA
Genbank
accession #
Fold
change
Symbol Gene
Transcription factors
NM_007678 −1.7 Cebpa CCAAT/enhancer binding protein
(C/EBP), alpha
NM_010234 −1.6 Fos FBJ osteosarcoma related oncogene
NM_009331 −1.6 Tcf7 Transcription factor 7, T-cell specific
NM_010703 −1.6 Lef1 Lymphoid enhancer binding factor 1
NM_008259 1.6 Foxa1 Forkhead box A1
NM_016768 1.7 Pbx3 Pre B-cell leukemia transcription factor 3
NM_207215 1.7 Phr1 Pam, highwire, rpm 1
NM_010574 1.7 Irx2 Iroquois related homeobox 2
NM_177338 2.8 Hmbox1 Homeobox containing 1
Development
NM_177905 −3.5 Piwil4 Piwi-like homolog 4 (Drosophila)
XM_897426 −2.9 Plekhk1 Pleckstrin homology domain containing,
family K member 1
NM_133245 −1.9 Eraf Erythroid associated factor
NM_011313 −1.8 S100a6 S100 calcium binding protein A6
NM_008970 −1.7 Pthlh Parathyroid hormone-like peptide
NM_010103 −1.7 Edil3 EGF-like repeats and discoidin I-like
domains 3
NM_007447 −1.7 Ang1 Angiogenin 1
NM_054077 −1.6 Prelp Proline arginine-rich end leucine-rich
repeat
NM_009114 −1.6 S100a9 S100 calcium binding protein A9
NM_009627 −1.5 Adm Adrenomedullin
XM_134149 1.5 Fath Fat tumor suppressor homolog
NM_172537 1.5 Sema6d Semaphorin 6D
NM_011350 1.6 Sema4f Semaphorin 4f
NM_010164 1.7 Eya1 Eyes absent 1 homolog
NM_031166 1.9 Idb4 Inhibitor of DNA binding 4
NM_008520 1.9 Ltbp3 Latent transforming growth factor beta
binding protein 3
NM_007963 1.9 Evi1 Ecotropic viral integration site 1
NM_010181 2.4 Fbn2 Fibrillin 2
NM_011674 2.5 Ugt8 UDP-glucuronosyltransferase 8
Signal transduction
NM_008731 −4.20 Npy2r Neuropeptide Y receptor Y2
NM_007413 −2.9 Adora2b Adenosine A2b receptor
NM_023635 −2.6 Rab27a RAB27A
NM_013875 −2.2 Pde7b Phosphodiesterase 7B
NM_144547 −2.0 Amhr2 Anti-mullerian hormone type 2 receptor
NM_007592 −2.0 Car8 Carbonic anhydrase 8
NM_010407 −1.8 Hck Hemopoietic cell kinase
NM_009217 −1.7 Sstr2 Somatostatin receptor 2
NM_021409 −1.6 Pard6b Partitioning defective 6 homolog beta
NM_009062 −1.6 Rgs4 Regulator of G-protein signaling 4
NM_021099 −1.6 Kit Kit oncogene
NM_025730 −1.5 Lrrk2 Leucine-rich repeat kinase 2
NM_138650 −1.5 Dgkg Diacylglycerol kinase, gamma
NM_019725 −1.5 Tle2 Transducin-like enhancer of split 2
homolog
NM_020505 −1.5 Vav3 Vav 3 oncogene
NM_145566 1.5 Hrbl HIV-1 Rev binding protein-like
NM_013846 1.6 Ror2 Receptor tyrosine kinase-like orphan
receptor 2
XM_130346 1.7 Gpr155 G protein-coupled receptor 155
NM_019688 1.7 Rapgef4 Rap guanine nucleotide exchange
factor 4
NM_022721 1.7 Fzd5 Frizzled homolog 5
NM_008965 1.7 Ptger4 Prostaglandin E receptor 4
Table 2 (continued)
Genbank
accession #
Fold
change
Symbol Gene
Signal transduction
NM_009827 1.9 Cckar Cholecystokinin A receptor
NM_172815 2.9 Rspo2 R-spondin 2 homolog
Cell adhesion
NM_001010937 −4.4 Gjb6 Gap junction membrane channel protein
beta 6
NM_018857 −2.3 Msln Mesothelin
XM_356226 −1.9 Fat3 Fat tumor suppressor homolog 3
NM_133721 −1.7 Itga9 Integrin alpha 9
NM_007734 −1.6 Col4a3 Procollagen, type IV, alpha 3
NM_009868 −1.5 Cdh5 Cadherin 5
NM_009903 1.7 Cldn4 Claudin 4
NM_028078 1.7 Jam4 Junction adhesion molecule 4
NM_007667 1.7 Cdh8 Cadherin 8
NM_178382 1.8 Flrt3 Fibronectin leucine rich transmembrane
protein 3
NM_172862 1.8 Frem2 Fras1 related extracellular matrix
protein 2
NM_009864 1.9 Cdh1 Cadherin 1
NM_007883 2.3 Dsg2 Desmoglein 2
NM_028523 2.3 Dcbld2 Discoidin, CUB and LCCL domain
containing 2
NM_007663 2.9 Cdh16 Cadherin 16
NM_019394 30.3 Mia1 Melanoma inhibitory activity 1
Transport
NM_009701 −10.8 Aqp5 Aquaporin 5
XM_130308 −2.9 Lrp2 Low density lipoprotein receptor-related
protein 2
NM_133969 −2.7 Cyp4v3 Cytochrome P450, family 4,
subfamily v, polypeptide 3
NM_013855 −2.5 Abca3 ATP-binding cassette, sub-family A
member 3
NM_172621 −2.0 Clic5 Chloride intracellular channel 5
NM_027491 −1.9 Rragd Ras-related GTP binding D
NM_029310 −1.8 RIKEN cDNA 1700008G05 gene
NM_011403 −1.8 Slc4a1 Solute carrier family 4 member 1
XM_130038 −1.6 Cubn Cubilin
NM_153522 −1.6 Scn3b Sodium channel, voltage-gated, type III,
beta
NM_009197 1.5 Slc16a2 Solute carrier family 16 member 2
NM_027052 1.5 Slc38a4 Solute carrier family 38, member 4
NM_025383 1.6 Necap2 NECAP endocytosis associated 2
NM_013569 1.6 Kcnh2 Potassium voltage-gated channel,
subfamily H
NM_011985 1.7 Mmp23 Matrix metalloproteinase 23
NM_172778 1.9 Maob Monoamine oxidase B
NM_053079 1.9 Slc15a1 Solute carrier family 15, member 1
NM_018732 2.1 Scn3a Sodium channel, voltage-gated, type III,
alpha polypeptide
NM_172613 2.4 Atp13a4 ATPase type 13A4
NM_008557 2.4 Fxyd3 FXYD domain-containing ion transport
regulator 3
Lipid metabolism
NM_009127 −30.3 Scd1 Stearoyl–Coenzyme A desaturase 1
NM_028765 −10.8 Acoxl Acyl–Coenzyme A oxidase-like
NM_011134 −8.8 Pon1 Paraoxonase 1
NM_010052 −4.1 Dlk1 Delta-like 1 homolog
NM_145376 −4.1 Aytl2 Acyltransferase like 2
NM_147779 −2.7 Sftpb Surfactant associated protein B
(continued on next page)
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Genbank
accession #
Fold
change
Symbol Gene
Lipid metabolism
NM_023608 −2.7 Gdpd2 Glycerophosphodiester
phosphodiesterase domain containing 2
NM_009128 −1.9 Scd2 Stearoyl–Coenzyme A desaturase 2
NM_008149 −1.5 Gpam Glycerol-3-phosphate acyltransferase,
mitochondrial
NM_175556 1.5 Plch2 Phospholipase C, eta 2
NM_011921 1.6 Aldh1a7 Aldehyde dehydrogenase family 1,
subfamily A7
NM_146106 1.6 Lyplal1 Lysophospholipase-like 1
NM_001004762 2.1 Pla2g4c Phospholipase A2, group IVC
(cytosolic, calcium-independent)
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high abundance in the embryonic lung was Mia1.
MIA was originally isolated from a human melanoma cell
line as a protein that was able to both suppress proliferation and
change the morphology of malignant melanoma cells in vitro
(Blesch et al., 1994). MIA is a small protein that is translated as a
131 amino acid precursor, which is subsequently processed to
107 amino acids by N-terminal cleavage of a hydrophobic signal
peptide (Blesch et al., 1994). MIA is the prototypical member of
a family of four proteins that share sequence and structural
homology, including conserved cysteine residues and Src
homology 3 (SH3)-like domains (Lougheed et al., 2001; Stoll
et al., 2001).WhereasMIAwas initially identified as an inhibitor
of melanoma cell proliferation (Blesch et al., 1994; Bogdahn et
al., 1989), further investigation revealed that MIAwas elevated
in malignant melanoma cells in vivo (Bosserhoff et al., 1999)
and in vitro (van Groningen et al., 1995). Furthermore, high
serumMIA levels correlated with advanced stages of melanoma
(Bosserhoff et al., 1997a; Stahlecker et al., 2000) and with a poor
prognosis following surgery (Guba et al., 2002). Mia1 was also
identified as the gene CD-RAP in a differential display screen
comparing differentiating bovine chondrocytes with those in
which differentiation was suppressed by RA (Dietz and Sandell,
1996). Expression of CD-RAP coincides with the initiation of
chondrogenesis and remains high throughout development of
the cartilaginous skeleton (Bosserhoff et al., 1997b).
We observed that Mia1 was abundantly expressed in the
epithelium during early lung patterning. One potential explana-
tion for this pattern of expression can be drawn from
observations made on metastatic melanoma cells. It has been
shown that MIA binds to type III fibronectin repeats, thereby
making these sites unavailable for binding to cell surface
integrins (Bosserhoff et al., 2001; Stoll et al., 2001). MIA
interacts with integrins α4β1 and α5β1, downregulates their
activity, and reduces MAP Kinase signaling (Bauer et al., 2006).
The predicted result of such competition was that the melanoma
cells could detach from the extracellular matrix and metastasize
(Bosserhoff et al., 2003b). Indeed, overexpression of MIA
enhanced the metastatic and invasive properties of hamster
melanoma cells, and antisense inhibition of Mia1 reduced their
metastatic potential (Guba et al., 2000). MIA also increased the
invasiveness of pancreatic cancer cells without affecting theirproliferation (El Fitori et al., 2005). Considered with these
results, our observations are consistent with a model in which
MIA facilitates epithelial invasion of the mesenchyme by
preventing cells from attaching to ECM molecules. Mia1
expression was highest during the embryonic and pseudogland-
ular stages of lung development, when the epithelium is actively
invading the surrounding mesenchyme to pattern the pulmonary
tree. This phase of lung development in the mouse ends with the
initiation of the canalicular phase, which occurs on day E16.5
(Ten Have-Opbroek, 1991). Distal epithelial morphogenesis
continues during the canalicular phase, with terminal bronch-
ioles lengthening and subdividing into short acinar tubules
consisting of cuboidal epithelial cells that are beginning to
differentiate into type I and type II alveolar cells. Continued
expansion of the most distal epithelium into the mesenchyme
would explain the persistence of Mia1 expression seen in these
acini on days E16.5–17.5 (Figs. 1I, J).
The E11.5 tracheal epithelium does not express Mia1, but
did so when it was induced to branch by recombination with
distal lung mesenchyme. Thus Mia1, like Sftpc, was expressed
in epithelial cells as a specific response to inductive cues
produced by lung mesenchyme. These include members of the
FGF family, since treatment of intact lung explants with the
FGF receptor antagonist SU5402 drastically reduced Mia1
expression. Our observation that SU5402 also inhibited Mia1
expression in mesenchyme-free lung epithelial rudiments
cultured with FGFs demonstrated that FGFs directly affect
Mia1 expression. The MAP Kinase/Erk and PI3-Kinase/Akt
pathways are both used to propagate FGF signaling. We found
that either U0126 (a MEK inhibitor) or LY294002 (a PI3-
Kinase inhibitor) significantly inhibited Mia1 expression in
whole lung explants. This could mean that either FGF
stimulation of Mia1 is mediated by both pathways, or that
Mia1 is also regulated by another factor(s) that signals through
either of these pathways.
The fact that Mia1 expression was highest in the morpho-
genetically active signaling centers of the most distal epithelium
further supports a role for MIA in mediating epithelial–
mesenchymal interactions and facilitating epithelial expansion.
A role for MIA in epithelial expansion may not be restricted to
the lung, since we also observed that the branching epithelia of
the kidney, submandibular salivary gland, and pancreas all
expressed abundant Mia1 on day E15.5 (data not shown). Mia1
is also expressed in the branching epithelium of the developing
mammary gland (Xie et al., 2000). Interestingly, the pattern of
Mia1 expression in the developing mammary gland is
dynamically similar to what we observed in the lung-expression
begins on day E11.5 and ceases on E16.5. The observation that
Mia1 is also expressed in carcinogen-induced mammary tumors
(Lu et al., 1997) has led to speculation that Mia1 may act as a
fetal oncogene (Xie et al., 2000).
Our results showing that the hyperplastic epithelial growths
induced by FGF7 or FGF10 express Mia1 support the
hypothesis that MIA plays a role in epithelial expansion. The
lungs of E18.5 SP-C/FGF7 mice showed diffuse epithelial cell
hyperplasia in the parenchyma, which causes an increase in
overall lung size and volume (Tichelaar et al., 2000). Virtually
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positive for Mia1. The results with CCSP/FGF10 fetuses were
even more informative. In these lungs we observed focal
adenoma-like regions where Mia1 was intensely expressed,
whereas surrounding areas of normal parenchyma showed no
signal. Therefore only those cells that were engaged in
morphogenetic activity, albeit abnormal, expressed Mia1.
Recent studies using a soluble dominant-negative form of the
FGFR2b (Hokuto et al., 2003), or misexpression of the FGF
signaling antagonist Sprouty-4 (Perl et al., 2003), have shown
that FGF signaling is most critical during the embryonic and
pseudoglandular stages of lung development, when Mia1
expression is highest. Misexpression of FGF7 and FGF10
may therefore cause epithelial cells to remain in a state of
embryonic/pseudoglandular patterning.
The possibility that Mia1 may act as a fetal oncogene in the
mammary gland epithelium should also be considered for the
lung. Although we observed that Mia1 is expressed in the
adenoma-like growths in the lungs of CCSP/FGF10 mice, it is
important to note that these hyperplastic regions are not
independent tumors, because they regress when doxycycline
is withdrawn and FGF10 stimulation subsequently ends (Clark
et al., 2001). We therefore examined urethane-induced lung
tumors and found that Mia1 expression was increased more
than 10-fold in these progressive neoplasms. These observa-
tions support the possibility that Mia1 acts as a fetal oncogene.
We do not currently know if this increase inMia1 is restricted to
lung tumors induced by chemical carcinogens, or if these
observations extend to human lung tumors.
Treating cultured lung explants with RA disrupted normal
branching and concomitantly suppressed Mia1 expression,
which also correlates with a role for Mia1 in lung branching
morphogenesis. Previous studies on its effects on cultured lung
explants showed that RA suppresses expression of epithelial
differentiation markers Sftpa, Sftpb, Sftpc, and “proximalizes”
the lung (Cardoso et al., 1996). Since our ontogeny study showed
that Mia1 expression was highest in the distal lung epithelium,
the RA-induced decrease in Mia1 may therefore reflect a
suppression of distal epithelial differentiation in general.
While MIA appears to be involved in epithelial expansion
during patterning of the pulmonary epithelium, its silencing
may be required for normal lung development to proceed,
particularly the differentiation of alveolar type II cells. Our
observation that exogenous MIA caused significant decreases in
expression of the type II cell differentiation markers Sftpa,
Sftpb, Sftpc and Abca3 in cultured lung explants led us to
generate transgenic mice in which we induced continued MIA
expression after E16.5. We did not observe expanded
morphogenesis in these fetal lungs, but instead saw decreased
formation of acini and a lack of the mesenchymal thinning that
normally occurs towards the end of gestation. This may indicate
that MIA by itself is not able to facilitate morphogenesis and
must work in concert with other factors. It is also possible that
the levels of MIA expressed in SP-C/MIA mice were so high
that normal cell–ECM interactions were disrupted.
Importantly, we found that continued expression of MIA
resulted in neonatal death from respiratory failure, which wasaccompanied by changes in the expression of many genes. The
observed decreases in Sftpb, Abca3, and Cebpa are notable,
because deletion of any of these genes results in respiratory
failure at birth (Ban et al., 2007; Clark et al., 1995; Fitzgerald et
al., 2007; Martis et al., 2006). Furthermore, we found that the
amount of SatPC, the most important phospholipid for lowering
surface tension at the air–liquid interface in the alveolus, was
only 40% of normal levels, which is consistent with a
phenotype of respiratory failure (Ikegami et al., 1980). The
reduced amount of SatPC correlated with decreased expression
of the Aytl2 gene, which encodes a lysophosphatidylcholine
acyltransferase (Chen et al., 2006) involved in the critical
deacylation/reacylation pathway of SatPC synthesis (Mason
and Nellenbogen, 1984).
One possible reason for the inhibition of type II cell
differentiation seen when MIA was misexpressed is that MIA
prevented the cells from interacting with critical ECM
molecules. MIA has been shown to directly interact with both
fibronectin and laminin (Bosserhoff et al., 2003b; Stoll et al.,
2001), and prevents melanoma cells from adhering to these
matrix proteins (Bosserhoff et al., 2003b). MIA has also been
shown to interact with integrins α4β1 and α5β1, which bind
fibronectin, to reduce their activity and signaling through the
MAP Kinase/Erk pathway (Bauer et al., 2006). The ability of
MIA to prevent cells from interacting with laminin and other
ECM molecules presents one possible explanation for the
observed phenotype of respiratory failure in SP-C/MIA mice.
Several studies have shown that type II cells isolated from late-
gestation fetuses (Chelly et al., 1999) or adult animals (Rice et
al., 2002; Shannon et al., 1987, 1990) require a laminin-rich
substratum in order to functionally differentiate in vitro.
Furthermore, targeted deletion of laminin α5 in lung epithelial
cells caused a marked reduction in the number of differentiated
type II cells (Nguyen et al., 2005). Mice with a specific ablation
of the nidogen binding site in the laminin γ1 chain exhibited
immature lungs that contained reduced numbers of air saccules
and thickened mesenchyme (Willem et al., 2002). Neonatal
mice with a compound genetic ablation of nidogen 1 and 2 also
showed immature lung morphology, and likewise died at birth
from respiratory failure (Bader et al., 2005). We observed the
same immature lung morphology in SP-C/MIAmice that died at
birth, which was correlated with reductions in several key
molecular components of the pulmonary surfactant system.
Although this possibility will require more experimentation for
its validation, we speculate that the 30-fold increase in Mia1
expression in the lungs of SP-C/MIA mice may act in a
dominant-negative fashion to block a critical type II cell–
laminin interaction. Alternatively, high levels of MIA may
disrupt the interaction of the nidogens with laminin, which is
required to produce a basement membrane capable of support-
ing type II cell differentiation.
Whatever its role in branching morphogenesis of the lung
and other epithelia may be, Mia1 by itself is not essential for
normal development. Mice with a targeted deletion of Mia1
were viable and showed no major organ abnormalities, although
the lung was not specifically examined. These mice did,
however, exhibit subtle defects in cartilage formation at the
454 S. Lin et al. / Developmental Biology 316 (2008) 441–455ultrastructural level (Moser et al., 2002). The lack of phenotype
in Mia1 null mice might be attributed to the fact that MIA is a
member of a family of four homologous proteins that includes
Otor (Mial, Fdp) (Cohen-Salmon et al., 2000; Robertson et al.,
2000), Mia2 (Bosserhoff et al., 2003a), and Tango (Bosserhoff
and Buettner, 2002). Since these proteins are secreted, it is
possible that one or more of them serves a compensatory role in
Mia1 null mice. However, we did not detect Otor and Mia2 in
the E12.5 lung by RT-PCR (data not shown). Our data suggest
that silencing ofMia1may precede type II cell differentiation in
late gestation. Deletion of Mia1 might therefore lead to
premature type II cell differentiation, a phenotype that might
not be deleterious to the neonates.
In summary, we have used DNA microarray technology to
identify a panel of genes that are differentially expressed in the
embryonic lung vs. the trachea. We have shown that one of
these genes,Mia1 exhibits a dynamic pattern of expression over
the course of lung development. Mia1 encodes an ECM protein
that is regulated by FGFs and is highly expressed in lung
epithelial cells that are undergoing FGF-induced dysmorpho-
genesis.Mia1 is also increased in urethane-induced independent
lung tumors. Misexpression of Mia1 results in neonatal death
from respiratory failure secondary to immaturity of the
surfactant system, suggesting the possibility that the decrease
in Mia1 observed during late gestation may be required to
facilitate type II cell differentiation.
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